Table II.
Mortality of patients with Pneumocystis jirovecii pneumonia treated with echinocandins.
| Author, year | Characteristic | Mortality (%) | (Refs.) |
|---|---|---|---|
| Zhang et al, 2006; Hof and Schnülle, 2008 | Used EC as monotherapyin salvage regimen | 0/2 (0) | (8,19) |
| Kamboj et al, 2006 | EC as initial regimen | 1/8 (12.5) | (11) |
| Kamnoj et al, 2006; Zhang et al, 2012; Kim et al, 2013; Tu et al, 2013 | Total mortality | 7/24 (29.2) | (11,13,15,16) |
| Kamnoj et al, 2006; Zhang et al, 2012; Kim et al, 2013; Tu et al, 2013 | Used EC as combination therapy in salvage regimen | 5/14 (35.7) | (11,13,15,16) |
| Kamnoj et al, 2006; Zhang et al, 2012; Kim et al, 2013; Tu et al, 2013 | EC as salvage regimen | 5/16 (31.5) | (11,13,15,16) |
| Kamboj et al, 2006; Kim et al, 2013 | Treatment without steroid regimen | 5/12 (41.7) | (11,15) |
| Zhang et al, 2012; Kim et al, 2013 | EC+(TMP-SMZ+PRI+CLI) | 2/3 (66.7) | (13,15) |
| Zhang et al, 2012; Tu et al, 2013 | Treatment with steroid regimen | 2/12 (16.7) | (13,16) |
| Kim et al, 2013 | EC+(AT+PRO)/(PRI+CLI)a | 1/1 (100) | (15) |
| Kim et al, 2013; Tu et al, 2013 | EC+TMP-SMZin salvage regimen | 2/9 (22.2) | (15,16) |
| Kamnoj et al, 2006 | Used EC as monotherapyin initial regimen | 1/2 (50.0) | (11) |
| – | Used ECplusTMP-SMZin initial regimen | 0/6 (0) | – |
| – | EC+(TMP-SMZ+CLI) | 0/1 (0) | – |
a
Following treatment for 2 weeks, regimen of AT+PRO shifted to regimen of PRI+CLI. EC, echinocandins; TMP-SMZ, trimethoprim/sulfamethoxazole; CLI, clindamycin; AT, atovaquone; PRO, proguanil; PRI, primaquine.